605199.SHG Hainan Huluwa Pharmaceutical Group Co Ltd
- Market cap
- CNY 2.12B
- P/E
- -
- P/B
- 6.96x
- ROE
- -75.8%
- Dividend yield
- 1.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 605199.SHG undervalued?
Graham numberThe Graham number of Hainan Huluwa Pharmaceutical Group Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hainan Huluwa Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Hainan Huluwa Pharmaceutical Group Co Ltd yet.
Hainan Huluwa Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of digestive system, respiratory system, anti- infective, anti-virus and other fields in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. The company was founded in 2005 and is based in Haikou, China.
Full company profileHainan Huluwa Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hainan Huluwa Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 487M | 655M | 984M | 1.31B | 1.16B | 1.35B | 1.52B | 1.80B | 1.41B | 901M | 482M |
| Gross Profit | 194M | 317M | 603M | 808M | 717M | 807M | 871M | 902M | 669M | 264M | 79.2M |
| Operating Income | 37.4M | 34.2M | 117M | 142M | 134M | 66.6M | 96.6M | 28.5M | -267M | -160M | -123M |
| EBITDA | 82.9M | 78.5M | 163M | 197M | 187M | 145M | 162M | 97.9M | -164M | -128M | -191M |
| Net Income | 33.8M | 22.1M | 101M | 120M | 122M | 72.1M | 85.7M | 10.9M | -274M | -287M | -227M |
| EPS | 0.21 | 0.13 | 0.31 | 0.33 | 0.32 | 0.18 | 0.21 | 0.03 | -0.69 | -0.72 | -0.57 |
| Balance Sheet | |||||||||||
| Total Assets | 536M | 807M | 1.09B | 1.09B | 1.52B | 1.76B | 2.31B | 3.06B | 2.96B | 2.60B | 2.42B |
| Total Liabilities | 407M | 456M | 487M | 443M | 605M | 830M | 1.30B | 1.90B | 2.22B | 2.14B | 2.07B |
| Shareholders' Equity | 129M | 351M | 605M | 644M | 916M | 928M | 1.01B | 1.12B | 701M | 413M | 299M |
| Cash & Short-term Investments | 62.2M | 82.6M | 181M | 154M | 346M | 488M | 480M | 523M | 254M | 78.2M | 38.9M |
| Total Debt | 228M | 146M | 142M | 153M | 283M | 499M | 684M | 1.16B | 1.00B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 65.0M | 90.0M | 31.8M | 145M | 3.30M | 102M | 239M | 28.3M | -149M | 137M | - |
| Capital Expenditure | 41.0M | 158M | 72.8M | 58.4M | 59.4M | 138M | 392M | 489M | 156M | 83.7M | 17.0M |
| Free Cash Flow | 24.0M | -67.6M | -41.0M | 86.1M | -56.1M | -35.1M | -154M | -461M | -305M | 53.2M | 72.0M |
| Ratios | |||||||||||
| ROE | 26.2% | 6.3% | 16.6% | 18.7% | 13.3% | 7.8% | 8.5% | 1.0% | -39.2% | -69.6% | -75.8% |
| ROA | 6.3% | 2.7% | 9.2% | 11.1% | 8.0% | 4.1% | 3.7% | 0.4% | -9.3% | -11.0% | -9.4% |
| Net Profit Margin | 6.9% | 3.4% | 10.2% | 9.2% | 10.5% | 5.3% | 5.7% | 0.6% | -19.4% | -31.9% | -47.1% |
| Debt to Equity | 1.77x | 0.42x | 0.24x | 0.24x | 0.31x | 0.54x | 0.67x | 1.04x | 1.43x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hainan Huluwa Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 1.58%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 16, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 33.6M | 0.08 | - |
| 2024 | CNY 92.2M | 0.23 | - |
| 2023 | CNY 31.6M | 0.09 | 290.9% |
| 2022 | CNY 14.4M | 0.04 | 16.7% |
| 2021 | CNY 60.0M | 0.15 | 83.2% |
| 2020 | CNY 8.00M | 0.02 | 6.6% |
| 2019 | CNY 81.0M | 0.22 | 67.3% |
| 2018 | CNY 80.6M | 0.25 | 80.1% |
| 2017 | CNY 13.5M | 0.08 | 60.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hainan Huluwa Pharmaceutical Group Co Ltd
- Insiders 72.86%
- Institutions 1.00%
- Public & others 26.14%
- Shares outstanding 400M
- Free float 173M
Hainan Huluwa Pharmaceutical Group Co Ltd company profile
- Company name
- Hainan Huluwa Pharmaceutical Group Co Ltd
- Ticker
- 605199.SHG
- ISIN
- CNE100004223
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,103
- Fiscal year end
- December
- Address
- No. 30, Anyu 1st Road, Haikou, China, 571157
- Phone
- 86 898 6861 2158
- Website
- huluwayaoye.com
About Hainan Huluwa Pharmaceutical Group Co Ltd
Hainan Huluwa Pharmaceutical Group Co., Ltd. research, develops, produces, and sells drugs in the areas of digestive system, respiratory system, anti- infective, anti-virus and other fields in China. It offers pediatrics, gynecology, antibiotics, respiratory, digestive system, cardiovascular and cerebrovascular, nourishment, and other medicine products. The company was founded in 2005 and is based in Haikou, China.
Hainan Huluwa Pharmaceutical Group Co Ltd management
7- Ms. Jinping LiuGM & Chairman of the Board · born 1970
- Ms. Hui YuFinancial Director, Deputy GM & Director · born 1984
- Mr. Qingtao WangSecretary · born 1982
- Mr. Tianbao WeiDeputy General Manager · born 1967
- Wei LiAccounting Supervisor
- Ms. Jun Ling LiDeputy GM & Director · born 1968
- Mr. Pei Hu LiDeputy General Manager · born 1973